The Food and Drug Administration has given AbbVie its blessing for Qulipta (atogepant) for the preventive treatment of episodic migraines in adults.
Qulipta is the first and only oral calcitonin gene-related peptide receptor antagonist (gepant) specifically developed for the preventive treatment of migraine.
[Read more: AbbVie gets FDA nod for Skyrizi]
“Millions of people living with migraine often lose days of productivity each month because attacks can be debilitating. Qulipta can help by reducing monthly migraine days with a once-daily, oral dose that works quickly and continuously,” said Michael Severino, vice chairman and president of AbbVie. “We are proud that AbbVie is now the only pharmaceutical company to offer three products across the full spectrum of migraine treatment, which include preventive therapies for chronic and episodic migraine and an acute treatment for migraine attacks.”
[Read more: Impel NeuroPharma intros migraine treatment Trudhesa]
According to AbbVie, Quilipta will be available in early October.